All methods were performed in accordance with the relevant guidelines and regulations.
Table of Contents
Human peripheral lung tissue collection
Lung tissue was obtained from 7 patients with very severe emphysema (GOLDIV) who underwent lung volume reduction surgery, and had quit smoking for at least 6 months before the surgery. These patients were prescribed combination therapy of inhaled corticosteroids and long-acting β2-agonists, tiotropium/ipratropiumbromide and salbutamol, on demand. In addition, lung tissue was obtained from 6 control subjects with normal lung function (without cough and/or sputum production), and 4 moderate (GOLDII) COPD patients undergoing resection of a solitary peripheral tumor. For all subjects, a history of respiratory diseases other than COPD as well as increased respiratory complaints or respiratory tract infection during the 4 weeks preceding the study were considered as criteria for exclusion. The study was approved by the medical ethical committee of the Maastricht University Medical Center+ (MUMC+) (MEC 02-043.3). All subjects gave their informed consent in writing. Patient characteristics and clinical information are shown in Table 1.
Undifferentiated PBEC: collection, isolation and proliferation
Lung tissue used for the isolation of PBEC was obtained from the Maastricht Pathology Tissue Collection (MPTC). Collection, storage and use of tissue and patient data were performed in agreement with the “Code for Proper Secondary Use of Human Tissue in the Netherlands” (www.fmwv.nl). The scientific board of the MPTC approved the use of materials for this study under MPTC2010-019. In addition, the local medical ethical committee approved the use of human tissue (METC 2017-0087).
Isolation, culture and characterization of cells was performed by the Primary Lung Culture (PLUC) facility at the MUMC+ as previously described35,36. The PLUC facility provided PBEC isolated from resected bronchus rings remote from the diseased areas of patients undergoing lung surgery due to lung cancer at MUMC+ . PBEC from 7 donors without known history of COPD and 4 donors with known history of COPD (GOLDII) were provided for this study. Characteristics of the subject are summarized in Table S1.
PBEC of 11 donors (5 × 105 cells, passage 1) were thawed, seeded and expanded in T75-flasks (passage 2; Corning Costar) on pre-coated growth areas (coating: 10 μg/mL human fibronectin, 30 μg/ml PureCol Type I Collagen Solution (Bovine) and 10 μg/mL bovine serum albumin (BSA) diluted in Hank’s Balanced Salt Solution (HBSS; no calcium, no magnesium, no phenol red) (Gibco)) in Lonza Bronchial Epithelial Basal Medium supplemented with Bronchial Epithelial Cell Growth Medium (BEGM) singlequots (except Gentamycin) (Lonza), BSA (1.5 µg/mL) and 1% penicillin/streptomycin (Gibco) (i.e., BEGM complete). After medium refreshment every other day, confluence was reached upon 5–6 days of proliferation. Thereafter, PBEC were trypsinized, counted and seeded in quintuplicate in pre-coated 6 wells, 12 wells or 60 mm dishes in BEGM complete medium. Medium was refreshed every other day. Upon 85% confluence, PBEC were starved overnight using Lonza Bronchial Epithelial Basal Medium supplemented with Bronchial Epithelial Cell Growth Medium singlequots (except gentamycin, bovine pituitary extract and epidermal growth factor) (Lonza), BSA (1.5 µg/mL) and 1% penicillin/streptomycin (Gibco) (i.e., BEGM starvation). The next day, after 24 h of starvation, undifferentiated PBEC were harvested in appropriate buffers for follow-up analysis.
Differentiated PBEC: collection, isolation, proliferation and differentiation
PBEC from COPD patients (n = 6) and control subjects (n = 6) were collected at the University Medical Center Marburg in agreement with local ethics regulations (Marburg 223/12) (code 223/12). Briefly, bronchoscopies were conducted according to American Thoracic Society consensus procedure. During bronchoscopy, bronchial brushings were collected using protected specimen brushes. Cells were scraped from the brush and incubated in 8 mL accutase with gentle agitation for 2 min before 8 min centrifugation at 300 rcf. Cells were resuspended in Airway Epithelial Cell Growth Medium (AEGM, Promocell) and seeded at 0.5 − 1 × 105 cells/cm2. After passaging once by trypsinization, cryostocks (2 × 106 cells/vial) were prepared upon 80% confluence (passage 2). Well differentiated PBEC cultures at ALI were generated by culturing passage 4 cells on 6.5 or 12 mm transwell inserts (Costar 3460) for 28 days in 1:1 AEGM/DMEM (Gibco) supplemented with 0.1 ng/mL retinoic acid as described previously37. Barrier formation was monitored by measuring electrical resistance with an EVOM2 and STX2 chopstick electrodes. During measurements, the basolateral compartment was filled with AEGM:DMEM, and the apical compartment with Phosphate-Buffered Saline. To calculate transepithelial electrical resistance (TEER) in Ω*cm2, the resistance of a blank transwell was subtracted from the resistance of the cell layer, followed by multiplication with the transwell surface area. Characteristics of the COPD and non-COPD donors are summarized in Table S1.
RNA isolation and synthesis of cDNA
Human peripheral lung tissue
Total RNA was isolated from crushed human lung tissue using the Qiagen RNeasy kit (Qiagen, USA) according to the manufacturer’s instructions. Following analysis of the quantity and quality of the total RNA by nanodrop, total RNA (400 ng) was reverse transcribed into cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Switzerland) following the instructions, including a no reverse transcription control and a no template control. Quantity and quality of the total RNA was verified by nanodrop analysis. Subsequently, cDNA was diluted in MilliQ (1:25) and stored in – 20 °C until use.
Undifferentiated PBEC
Total RNA was extracted from the undifferentiated PBEC (triplicates/donor) following the manufacturer’s protocol of the mirVana™ kit (Thermo Fisher Scientific, USA/NL). Following analyzing the quantity and quality of the total RNA by nanodrop, total RNA (800 ng) was reverse transcribed into cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche) following the instructions. Subsequently, cDNA was diluted in MilliQ (1:25) and stored in – 20 °C until use.
Differentiated PBEC
Differentiated PBEC (duplicates/donor) were lysed in TRIzol™ Reagent (Invitrogen™) at day 0 (day of air-lift; undifferentiated) and day 28 (28 days after air-lift; fully differentiated). Total RNA was extracted according to the manufacturer’s instructions (Catalog number 15596026 and 15596018, Invitrogen™) using glycogen blue co-precipitant (Thermo Fisher Scientific, USA). Nanodrop analysis of the RNA was conducted to verify quantity and quality of the total RNA. Next, cDNA synthesis was conducted from 350 ng total RNA using iScript™ cDNA synthesis kit (Bio-Rad, the Netherlands) including a no reverse transcription control and a no template control. cDNA dilutions were made in MilliQ (1:50) and stored at − 20 °C until use.
Real time quantitative PCR analysis
Real-time quantitative PCR amplification was conducted by pipetting 4.4 µL of cDNA (diluted 1:25 or 1:50 in MilliQ water), 5 µL 2xSensiMix™ SYBR® and Fluorescein Kit (Bioline, the Netherlands) and 0.6 µL forward and reverse primers for target genes in white LightCycler480 384 multiwell plates (Roche). Next, to study gene expression, these samples were analysed on the LightCycler480 machine (Roche) following the thermal cycling protocol: 10 min at 95 °C, 55 cycles of 10 s at 95 °C, 20 s at 60 °C. The list of target-specific primers used for qPCR analysis is shown in Table S2.
Qualitative analysis of melt curves and peaks using LightCycler480 software (Roche) was used to check for a-specific amplification which were subsequently excluded. Quantitative analysis (i.e., N-zero values: extrapolated relative amount of DNA at cycle zero) by LinRegPCR software 2014.x (the Netherlands) was used to calculate gene expression. Exclusion of samples with no amplification, no plateau phase, too low Cq value or outside 5% of group mean was automatically conducted during LinRegPCR analysis. GeNorm software 3.4 (Primerdesign, USA) was used to calculate the geometric mean of a combination of at least two and up to four housekeeping genes (Actin B (ACTB), Beta-2 Microglobulin (B2M), Peptidylprolyl Isomerase A (PPIA), Ribosomal Protein L13A (RPL13A)), which was used for normalization of the calculated expression of target genes.
Western blotting
Human peripheral lung tissue
Crushed human lung tissue was lysed in buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, 0.1% NP40 and protease inhibitor cocktail (Roche).
Undifferentiated PBEC
Undifferentiated PBEC (quintuplicates/donor) were lysed in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Nonidet P40 or 1% Triton X-100, 0.5% NA deoxycholate, 0.1% sodium dodecyl sulphate in MilliQ) including fresh non-stable components: PIC, 1 mM sodium orthovanadate.
Differentiated PBEC
Differentiated PBEC (duplicates/donor) were lysed at day 28 in Whole Cell Lysis buffer (20 mM Tris pH 7.4, 150 mM NaCl, 1% Nonidet P40 in MilliQ) including PhosSTOP Phosphatase and cOmplete, Mini, EDTA-free Protease Inhibitor cocktail tablets (both Roche).
Whole cell lysates of human peripheral lung tissue, undifferentiated and differentiated PBEC experiments were rotated for 30 min at 4 °C and centrifuged at 20,000 × g for 30 min at 4 °C. Thereafter, the total protein content was analysed by the Pierce™ BCA Protein Assay Kit (Catalog number 23225 and 23227, Thermo Fisher Scientific), and whole cell lysates were diluted in a final concentration of 0.19–0.71 µg/µL in 1 × Laemmli buffer (0.25 M Tris pH 6.8, 8% (w/v) sodium dodecyl sulphate, 40% (v/v) glycerol, 0.4 M Dithiothreitol, 0.02% (w/v) Bromophenol Blue). These diluted lysates were boiled for 5 min at 100 °C and subsequently stored at − 20 °C (undifferentiated PBEC) or − 80 °C (lung homogenates/differentiated PBEC) until further analysis. The protein ladders (Precision Plus Protein™ All Blue Standards #161-0373, Bio-Rad) and protein samples were loaded on a Criterion XT Precast 4–12% or 12% Bis–Tris gel (Bio-Rad), respectively singular peripheral lung homogenates per donor (7.14 µg/sample), pool of quintuplicates per undifferentiated PBEC donor (10 µg/sample), and duplicates per differentiated PBEC donor (2.75 µg/sample). Proteins were separated in 1 × MES running buffer (Bio-Rad) by electrophoresis (100–130 V for 1 h), whereafter proteins were transferred from the gel to a 0.45 µM Nitrocellulose Transfer membrane (Bio-Rad) by electroblotting (100 V for 1 h) using a Bio-Rad Criterion Blotter. To stain and correct for total protein content, the nitrocellulose membranes were incubated with Ponceau S staining (0.2% in 1% acetic acid; Sigma-Aldrich) which was visualized using the Amersham™ Imager 600 (GE Healthcare, the Netherlands). To stain the target-specific proteins, the Ponceau S staining was washed off and the membranes were blocked for 1 h in 3% (w/v) non-fat dry milk (Campina, the Netherlands) dissolved in Tween20 Tris-buffered saline (TBST; 20 mM Tris, 137 mM NaCl, 0.1% (v/v) Tween20, pH 7.6). After finishing blocking, the membranes were washed with TBST and incubated with a target-specific primary antibody diluted in 3% (w/v) BSA at 4 °C overnight. Next, the membranes were again washed with TBST and now incubated with a horseradish peroxidase-conjugated secondary antibody diluted in 3% (w/v) non-fat dry milk in TBST for 1 h at room temperature. To visualize the target proteins, the membranes were washed with TBST, stained with 0.25-1 × Supersignal West FEMTO and 0.5-1 × Supersignal West PICO Chemiluminescent Substrate (Thermo Fisher Scientific), and imaged using the Amersham™ Imager 600. The list of primary and secondary antibodies used for western blotting is shown in Table S3. The Image Quant software (GE Healthcare) was used for quantification of the total protein content and target-specific proteins. Total protein content was quantified using the Ponceau S-stained images over the entire size range of proteins (250 kDa-10 kDa). This total protein content was used as normalization factor for (quantification of) target-specific proteins. Because several proteins of interest were detected on a similar gel, which is possible due to their difference in molecular mass, correction for total protein content/loading of these target proteins was based on the same Ponceau S staining. To specify, Gel I: HK2, DNM1L, OXPHOS, SQSTM1, TOMM20; Gel II: PRKN, BNIP3L, BNIP3, FUNDC1, PINK1, MAP1LC3B; Gel III: NRF1, TFAM, GABARAPL1, ESRRA.
Image acquisition: equipment and settings
We performed chemiluminescence capturing with automatic or manual exposure time as described in the Operating Instructions of the Amersham™ Imager 600 (GE Healthcare). A short pre-exposure is performed to determine the signal intensity. The system will use this information to calculate which exposure time will give the highest possible signal below saturation to enable accurate quantification of the sample.’ Manual exposure is only performed with a maximum duration of 5 min, in case the intensity of the image is inadequate (i.e., takes > 5–10 min) after automatic exposure, which is also suggested by the manufacturer’ instructions. Western blot images displayed in the (supplementary) figures of this manuscript have been adjusted for brightness and contrast equally throughout the picture. In addition, the Ponceau S band (37, 50, 70 or 75 kDa) presented in the (supplementary) figures is representative for the total Ponceau S staining per sample. For illustration purposes of the protein abundance in the human peripheral lung tissue homogenates in the manuscript figures, examples of bands of the target proteins along with the corresponding normalization bands of the Ponceau S staining are shown of one patient/group, which is not always representative for the mean and changes in the whole patient group as quantified in the box plots (due to the variation between patients). In the Supplementary Figs.1–3, all western blot images of the target proteins along with the corresponding normalization bands of the Ponceau S staining of all subjects/group are shown of the peripheral lung tissue from non-COPD patients and COPD patients (GOLDII; GOLDIV) (single) (Figure S1), as well as images of undifferentiated PBEC (pool of quintuplicates) (Figure S2) and differentiated PBEC (duplicates) (Figure S3) from non-COPD patients and COPD patients.
Statistical data analysis
GraphPad Prism 8.0 software (La Jolla, USA) was used to display the data in box plot or scatter plot graphs. Data are presented as mean fold change of COPD patients (GOLDII or GOLDIV) relative to non-COPD patients (box plot: min to max; scatter plot: ± standard error of the mean (SEM)). Individual subjects are represented by open circles (non-COPD patients), squares (all COPD patients), triangles (COPD GOLDII patients) and diamonds (COPD GOLDIV patients). Quality of the mRNA data was analysed by melt curve/peak analysis using LightCycler480 software (Roche). In addition, exclusion of extreme outliers in the analysis of peripheral lung tissue was also based on box plot analysis (i.e., values more than three interquartile ranges from the end of a box) in IBM Statistics SPSS 25. Statistical differences were analysed using GraphPad Prism 8.0 software. First, normal distribution of the data was assessed with the Shapiro–Wilk test. Secondly, in case of testing the difference between two groups (COPD patients versus non-COPD patients), a two-tailed unpaired parametric t-test (normal distribution) or non-parametric Mann–Whitney test (non-normal distribution) was used. In addition, in case of testing the difference between three groups (COPD GOLDII patients or COPD GOLDIV patients relative to non-COPD patients), we used a one-way ANOVA and a Dunnett’s post-hoc test for multiple comparisons (normal distribution) or a Kruskal–Wallis test followed by a Dunn’s multiple comparisons test (non-normal distribution). Moreover, the correlation between lung function (forced expiratory volume in first second/forced vital capacity; FEV1/FVC) and transcript levels of investigated markers was evaluated by calculating the Spearman’s correlation coefficient (ρ) using IBM SPSS Statistics version 25.0.
With respect to the validation of the PBEC differentiation, TEER and gene expression data are presented as mean fold change of day 0 versus day 28 per patient group. Statistical differences between day 28 (differentiated) relative to day 0 (undifferentiated) in separate patient groups were tested using a two-tailed paired parametric t-test, or in case of non-normal distribution a paired nonparametric Wilcoxon test. Moreover, differences between day 28 (differentiated) of non-COPD relative to COPD patients were tested using a two-tailed unpaired parametric t-test (normal distribution) or non-parametric Mann–Whitney test (non-normal distribution). Statistical significance was considered if p-values were below 0.05 (*p < 0.05) or 0.01 (**p < 0.01) and a trend was indicated if below 0.1 (#p < 0.1).
Ethics approval and consent to participate
All methods were performed in accordance with the relevant guidelines and regulations. Human peripheral lung tissue: The study was approved by the medical ethical committee of the MUMC + , Maastricht, the Netherlands (MEC 02-043.3). All subjects gave their informed consent in writing. Undifferentiated PBEC: The scientific board of the MPTC approved the use of materials for this study under MPTC2010-019. In addition, the local medical ethical committee of the MUMC+ , Maastricht, the Netherlands approved the use of human tissue (METC 2017-0087). Differentiated PBEC: The study was approved by the local ethical committee Ethik-Kommission des Fachbereichs Humanmedizin der Philipps-Universität Marburg, Marburg, Germany (Marburg 223/12).

















